Navigation Links
Metabolex Appoints Donald Hill as Chief Financial Officer
Date:4/14/2008

HAYWARD, Calif., April 14 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that Donald M. Hill has joined the company as chief financial officer. Mr. Hill brings extensive financial and strategic planning experience to Metabolex, including expertise in business development, treasury management and controllership of large operating divisions. Mr. Hill joins Metabolex following more than 20 years in finance and corporate development management roles at Merck & Co., Inc., most recently as Assistant Treasurer, Global Capital Markets.

"The appointment of Don expands the depth of our already strong management team," said President and Chief Executive Officer Harold Van Wart, Ph.D. "Don's experience as a leader in a well respected, financially sophisticated pharmaceutical company, his experience in business development, and his strong analytical skills and strategic financial vision will be critical for us as we expand our product pipeline and move our clinical product candidates towards commercialization. With the company's four clinical product candidates and active discovery and preclinical development programs, Don's skills in financial planning and strategic product development will be invaluable."

Mr. Hill is a Chartered Financial Analyst (CFA), and holds a B.A. from the University of California, Berkeley and a Masters degree from the Sloan School of Management at the Massachusetts Institute of Technology.

About Metabolex

Metabolex is a privately-held biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, with an emphasis on type 2 diabetes. Metabolex has drawn on its deep understanding of diabetes to create a large database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company has four clinical-stage compounds: MBX-102/JNJ 39659100, which has recently completed a Phase 2/3 trial; MBX-2044, which has completed a Phase 2a trial; MBX-8025, currently being studied in a Phase 2 trial in patients with dyslipidemia; and MBX-2982, which has just commenced a Phase 1 trial. Ortho-McNeil, Inc. has the exclusive right to develop and commercialize MBX-102/JNJ 39659100. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com.


'/>"/>
SOURCE Metabolex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Biopure Appoints New Independent Auditor
2. Indivumed Appoints Annette Kassen as Vice President Clinical Research
3. ADVENTRX Appoints Vice President of Manufacturing
4. Egenix, Inc. Appoints Dr. Daniel Petrylak Chairman of Scientific Advisory Board
5. NanoLogix Inc. Provides Financial Update, Appoints Bert Pharis as New Director
6. Observant LLC Appoints Two New Directors to the Senior Management Team
7. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
8. Light Sciences Oncology Appoints David P. Holveck to Its Board of Directors
9. IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
10. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
11. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... Linda, Ca (PRWEB) , ... August 09, 2017 ... ... exosomes for regenerative medicine applications in the clinic is here. The team at ... EVs present in conditioned medium for clinical studies. , Dr. Travis Antes, ...
(Date:8/10/2017)... USA (PRWEB) , ... August 09, 2017 , ... ... partnered with four international biomedical optics laboratories — the Wellman Center for Photomedicine, ... Medical Laser Center Lübeck and the Beckman Laser Institute at University of California, ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... market news outlet had initiated coverage on Next Group Holdings, Inc. and see's ... consumer markets geared toward those that cannot engage in traditional banking services. According ...
(Date:8/8/2017)... ... August 08, 2017 , ... HumanZyme Inc., a leading supplier ... announced the launch of HumanKine® Interferon beta (IFN beta) expressed from ... activate Th1-type innate immune responses against viral and bacterial infection, and have antiproliferative ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... No two people are believed to ... York University Tandon School of Engineering and Michigan ... partial similarities between prints are common enough that ... and other electronic devices can be more vulnerable ... in the fact that fingerprint-based authentication systems feature ...
(Date:4/5/2017)... April 5, 2017 Today HYPR Corp. ... the server component of the HYPR platform is officially ... the end-to-end security architecture that empowers biometric authentication across ... has already secured over 15 million users across the ... of connected home product suites and physical access represent ...
Breaking Biology News(10 mins):